News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orion Corporation Receives First Marketing Authorisations For Bufomix Easyhaler® Product



4/15/2014 9:32:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler®, an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive pulmonary disease (COPD). In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator. The marketing authorisation covers two strengths (budesonide 160 µg / formoterol 4.5 µg and budesonide 320 µg / formoterol 9 µg) for the treatment of asthma and COPD in patients above 12 years.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES